Hospital costs of nosocomial multi-drug resistant <it>Pseudomonas aeruginosa</it> acquisition

• Main Authors: Morales Eva (Author), Cots Francesc (Author), Sala Maria (Author), Comas Mercè (Author), Belvis Francesc (Author), Riu Marta (Author), Salvadó Margarita (Author), Grau Santiago (Author), Horcajada Juan P (Author), Montero Maria (Author), Castells Xavier (Author)
• Format: Book
• Published: BMC, 2012-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

<p>Abstract</p> <p>Background</p> <p>We aimed to assess the hospital economic costs of nosocomial multi-drug resistant <it>Pseudomonas aeruginosa</it> acquisition.</p> <p>Methods</p> <p>A retrospective study of all hospital admissions between January 1, 2005, and December 31, 2006 was carried out in a 420-bed, urban, tertiary-care teaching hospital in Barcelona (Spain). All patients with a first positive clinical culture for <it>P. aeruginosa</it> more than 48 h after admission were included. Patient and hospitalization characteristics were collected from hospital and microbiology laboratory computerized records. According to antibiotic susceptibility, isolates were classified as non-resistant, resistant and multi-drug resistant. Cost estimation was based on a full-costing cost accounting system and on the criteria of clinical Activity-Based Costing methods. Multivariate analyses were performed using generalized linear models of log-transformed costs.</p> <p>Results</p> <p>Cost estimations were available for 402 nosocomial incident <it>P. aeruginosa</it> positive cultures. Their distribution by antibiotic susceptibility pattern was 37.1% non-resistant, 29.6% resistant and 33.3% multi-drug resistant. The total mean economic cost per admission of patients with multi-drug resistant <it>P. aeruginosa</it> strains was higher than that for non-resistant strains (15,265 vs. 4,933 Euros). In multivariate analysis, resistant and multi-drug resistant strains were independently predictive of an increased hospital total cost in compared with non-resistant strains (the incremental increase in total hospital cost was more than 1.37-fold and 1.77-fold that for non-resistant strains, respectively).</p> <p>Conclusions</p> <p><it>P. aeruginosa</it> multi-drug resistance independently predicted higher hospital costs with a more than 70% increase per admission compared with non-resistant strains. Prevention of the nosocomial emergence and spread of antimicrobial resistant microorganisms is essential to limit the strong economic impact.</p>

Item Description

10.1186/1472-6963-12-122
1472-6963